J. Foloppe, et al. IOVC 2024 Abstract available on the IOVC website – Download the abstract and the poster
Results for ""
We found 497 results for your search.
Investor Access Forum, October 15 & 16, 2024
TG4001+Avelumab vs Avelumab Single-Agent Phase II Update
link to webcast
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
TG4001 2024
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
SITC 2024
First Half 2024 Financial Results
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
H1 2024 FINANCIAL RESULTS
HealthTech Innovation Days (HTID) – Paris – September 17-18, 2024
Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
S. Champiat, et al. ESMO 2024 Abstract available on the ESMO website – Download the abstract and the poster
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
BT-001 ESMO
